tradingkey.logo
tradingkey.logo
Search

MaxCyte Inc

MXCT
Add to Watchlist
1.050USD
0.0000.00%
Close 07-31 16:00ETQuotes delayed by 15 min
112.13MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D

Today

0.00%

5 Days

-2.78%

1 Month

-14.63%

6 Months

+15.79%

Year to Date

-32.26%

1 Year

-48.53%

Key Figures
1.050Open
1.075High
478.64KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.45%Turnover Ratio
1.050Prev. Close
1.005Low
297.56KTurnover
LossP/E Static
0.65P/B
0.00%Div Yield TTM
-18.43%ROA
2.40052wk High
0.53Volume Ratio
-41.05MNet Profit
106.79MShares
-0.3669EPS TTM
1.45Beta
-21.30%ROE
0.64352wk Low
6.67%Amplitude
73.22%Gross Margin
112.13MMarket Cap
-4.16Reward/Risk
4.17%Risk Rate

TradingKey Stock Score of MaxCyte Inc

Currency: USD Updated: 2026-07-31

Key Insights

MaxCyte Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 70 out of 199 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.11.In the medium term, the stock price is expected to trend up.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

MaxCyte Inc's Score

Industry at a Glance

Industry Ranking
70 / 199
Overall Ranking
149 / 4281
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive+

MaxCyte Inc Highlights

StrengthsRisks
MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
Growing
The company is in a growing phase, with the latest annual income totaling USD 33.03M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 33.03M.
Overvalued
The company’s latest PE is -2.86, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 79.92M shares, decreasing 19.15% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 3.29K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.19.

Analyst Rating

Based on 6 analysts
Buy
Current Rating
4.107
Target Price
+306.68%
Upside Space

MaxCyte Inc News

More news coming soon, stay tuned...

Earnings Forecast

Analyst Rating

Based on 6 analysts
Buy
Current Rating
4.107
Target Price
+306.68%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

88
Total
4
Median
7
Average
Company name
Ratings
Analysts
MaxCyte Inc
MXCT
6
Intuitive Surgical Inc
ISRG
35
Boston Scientific Corp
BSX
34
Edwards Lifesciences Corp
EW
33
Veeva Systems Inc
VEEV
30
Thermo Fisher Scientific Inc
TMO
30
1
2
3
...
18

Indicators

Indicators
Sell(2)
Neutral(3)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
-0.060
Sell
RSI(14)
39.155
Neutral
STOCH(KDJ)(9,3,3)
21.110
Neutral
ATR(14)
0.086
High Vlolatility
CCI(14)
-72.354
Neutral
Williams %R
86.000
Oversold
TRIX(12,20)
-0.541
Sell
StochRSI(14)
100.000
Buy
Moving Average
Sell(4)
Neutral(0)
Buy(2)
Indicators
Value
Direction
MA5
1.036
Buy
MA10
1.092
Sell
MA20
1.209
Sell
MA50
1.183
Sell
MA100
1.005
Buy
MA200
1.165
Sell

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

MaxCyte Inc Info

MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
Ticker SymbolMXCT
CompanyMaxCyte Inc
CEOMasoud (Maher)
Websitehttps://www.maxcyte.com/

Shareholders

Shareholders
Shareholders
Proportion
Capricorn Fund Managers Ltd
7.65%
BlackRock Institutional Trust Company, N.A.
6.96%
River Global Investors LLP
5.13%
Vitruvian Partners LLP
4.71%
Vanguard Capital Management, LLC
3.72%
Other
71.83%

FAQs

What is the current price of MaxCyte Inc (MXCT)?

The current price of MaxCyte Inc (MXCT) is 1.05.

What is the symbol of MaxCyte Inc?

The ticker symbol of MaxCyte Inc is MXCT.

What is the 52-week high of MaxCyte Inc?

The 52-week high of MaxCyte Inc is 2.40.

What is the 52-week low of MaxCyte Inc?

The 52-week low of MaxCyte Inc is 0.64.

What is the market capitalization of MaxCyte Inc?

The market capitalization of MaxCyte Inc is 112.13M.

Is MaxCyte Inc (MXCT) currently rated as Buy, Hold, or Sell?

According to analysts, MaxCyte Inc (MXCT) has an overall rating of Buy, with a price target of 4.11.

What is the Earnings Per Share (EPS TTM) of MaxCyte Inc (MXCT)?

The Earnings Per Share (EPS TTM) of MaxCyte Inc (MXCT) is -0.42.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.